B
Batavia Biosciences
CDMO for viral vectors, vaccines and gene-therapy process development
About Batavia Biosciences
Batavia Biosciences is a Leiden-based biopharmaceutical CDMO focused on viral vectors, viral vaccines and related process development through clinical and commercial manufacturing. Spun out of TNO in 2010 as Batavia Biosciences B.V. (KVK 27362965), it offers cell-line generation, upstream and purification development, product characterisation and GMP manufacture for gene therapy and vaccine clients, with sites in Leiden and historically Woburn, Massachusetts. CJ CheilJedang acquired a controlling stake in December 2021 for about €195m; Batavia continues as an operating brand within CJ's red-bio/CDMO platform.
Source: Dealroom company dataAt a glance
- Outcome tier
- Colt$25–100M revenue
News
Open roles
Batavia Biosciences in the Leiden ecosystem
The Batavia Biosciences office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Bill & Melinda Gates Foundation
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Batavia Biosciences on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Batavia Biosciences on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.
